Trevi Therapeutics, Inc.

The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income, net on the Condensed Consolidated Statements of Comprehensive Loss.

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company s strategy and intentions for holding the marketable security.

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

These variables include the expected term that stock options will remain outstanding, expected common stock price volatility over the term of the stock options, risk-free interest rates and expected dividends.

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Expected Dividend The Black-Scholes valuation model calls for a single expected dividend yield as an input.

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Company currently has no history or expectation of paying cash dividends on its common stock.

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

If the Company s leases do not provide an implicit rate within the lease, the Company uses its incremental borrowing rate, based on information available at the commencement date of the lease to determine the present value of the lease payments.

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

All statements, other than statements of historical fact, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues and profitability, projected costs, prospects, plans and objectives of management, are forward-looking statements.

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

( Trevi or the Company ) is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis ( IPF ), non-IPF interstitial lung disease ( non-IPF ILD ), and refractory chronic cough ( RCC ).

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company s strategy and intentions for holding the marketable security.

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements.

SEC original ↗Trevi Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties.

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Legal Proceedings 26 Item 1A.

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

There are no material uncertainties regarding the tax positions that the Company has taken through June 30, 2026 and December 31, 2025 .

SEC original ↗Trevi Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026